Facing death, returning to life: A qualitative analysis of MDMA-assisted therapy for anxiety associated with life-threatening illness
In an interpretative phenomenological analysis of participant narratives from a pilot phase 2 trial, MDMA-assisted therapy for anxiety related to life‑threatening illness was reported to facilitate processing of trauma and grief, evoke mystical/existential experiences and reduce physiological arousal, yielding improved coping, reduced psychological symptoms, greater vitality and a reconnection to life. These accounts suggest MDMA‑AT may bolster emotional resilience in the face of illness relapse, though trial limitations temper conclusions and indicate the need for further study.
Abstract
Anxiety associated with life-threatening illness (LTI) is a pervasive mental health issue with a wide impact. A spectrum of traditional pharmacotherapies and psychotherapies are available, but offer varying success in reducing symptoms and improving quality of life. We explore a novel therapy for this condition by assessing prominent thematic elements from participant narrative accounts of a pilot phase 2 clinical trial of 3,4 Methylenedioxymethamphetamine-Assisted Therapy (MDMA-AT) for treating anxiety associated with LTI. Semi-structured qualitative interviews were conducted with a subset of adult participants 3 months following completion of this trial. This qualitative analysis sought to complement, clarify, and expand upon the quantitative findings obtained from the clinical trial to further understand the process and outcomes of the treatment. Interviews were coded and analyzed using an Interpretative Phenomenological Analysis (IPA) methodological framework. Participants described in detail their experiences from before, during and after the trial, which were analyzed and categorized into thematic clusters. Specifically, participants explored what they felt were important elements of the therapeutic process including processing trauma and grief, exploring mystical and existential experiences, engaging with the present moment with reduced physiological activation, and facing illness and existential fears. Outcomes of the treatment included increased ability to cope with LTI, reduced psychological symptoms, improved vitality and quality of life, and feeling more resourced. Participant narratives also showed a reconnection to life and greater emotional resilience in response to trauma and medical relapse. These findings are compared to similar treatments for the same indication. Limitations and challenges encountered in conducting this study are discussed along with implications for theory and clinical treatment.
Research Summary of 'Facing death, returning to life: A qualitative analysis of MDMA-assisted therapy for anxiety associated with life-threatening illness'
Introduction
Anxiety and existential distress are common sequelae of life-threatening illness (LTI), affecting functioning, quality of life and treatment adherence. While pharmacological and psychotherapeutic treatments exist, many patients continue to experience substantial anxiety, depression and post-traumatic stress related to diagnosis, medical procedures and the threat of recurrence. In recent decades, controlled trials of classic psychedelic medicines such as psilocybin and LSD combined with psychotherapy have shown promise for reducing distress in people with LTI; MDMA, although pharmacologically distinct, has demonstrated efficacy as an adjunct to trauma-focused psychotherapy and shares methodological features with other psychedelic‑assisted protocols. Barone and colleagues report a qualitative follow-up to a pilot Phase II randomised, double‑blind, placebo‑controlled clinical trial of MDMA‑assisted therapy (MDMA‑AT) for anxiety associated with LTI. The qualitative study aimed to complement and deepen understanding of the trial’s quantitative findings by analysing semi‑structured interviews conducted three months after treatment. Specific objectives were to identify key experiential themes across the treatment timeline (before, during and after MDMA‑AT), to characterise perceived mechanisms leading to sustained improvements, and to compare phenomenological similarities and differences with other psychedelic‑assisted treatments for the same indication.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Author
- APA Citation
Barone, W., Mitsunaga-Whitten, M., Blaustein, L. O., Perl, P., Swank, M., & Swift, T. C. (2022). Facing death, returning to life: A qualitative analysis of MDMA-assisted therapy for anxiety associated with life-threatening illness. Frontiers in Psychiatry, 13. https://doi.org/10.3389/fpsyt.2022.944849
References (23)
Papers cited by this study that are also in Blossom
Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Danforth, A. L., Grob, C. S., Struble, C. et al. · Psychopharmacology (2018)
Mithoefer, A. T., Mithoefer, M. C., Feduccia, A. A. et al. · Lancet Psychiatry (2018)
Jerome, L., Feduccia, A. A., Wang, J. B. et al. · Psychopharmacology (2020)
Mitchell, J., Bogenschutz, M. P., Lilienstein, A. et al. · Nature Medicine (2021)
Ching, T. H., Williams, M. T., Reed, S. et al. · Journal of Humanistic Psychology (2022)
Wolfson, P. E., Andries, J., Feduccia, A. A. et al. · Scientific Reports (2020)
Show all 23 referencesShow fewer
Barone, W., Beck, J., Mitsunaga-Whitten, M. et al. · Journal of Psychoactive Drugs (2019)
Belser, A. B., Agin-Liebes, G. I., Swift, T. C. et al. · Journal of Humanistic Psychology (2017)
Swift, T. C., Belser, A. B., Agin-Liebes, G. et al. · Journal of Humanistic Psychology (2017)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Nichols, D. E. · Journal of Psychoactive Drugs (1986)
Gorman, I., Belser, A. B., Jerome, L. et al. · Journal of Traumatic Stress (2020)
Sessa, B. · Neuroscience Letters (2016)
Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2009)
Dumont, G., Sweep, F., van der Steen, R. et al. · Social Neuroscience (2009)
Kamilar-Britt, P., Bedi, G. · Neuroscience and Biobehavioral Reviews (2015)
Rothberg, R. L., Azhari, N., Haug, N. A. et al. · Journal of Psychopharmacology (2020)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.